Celularity
NASDAQ: CELUFlorham Park, US · Founded 2018 · Delaware corporation · 3 known investors
Find your way into Celularity
430 people in our graph share verified history with the Celularity team — schools, employers, funds. One of them is your warm intro.
Mike Zakunlockedknows Beth Steinbrenner · together at Cornell (overlapped)
×6knows the team · via Cornell
knows the team · via Seton Hall University
×4knows the team · via University of California, College of the Law, San Francisco (formerly UC Hastings)
Celularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.
Founders & leadership
Celularity was founded in 2018 by Robert J. Hariri.
RJ
Robert J. HaririinFounder · Chairman and CEODr. Hariri is a neurosurgeon and researcher who discovered pluripotent stem cells derived from the placenta and co-discovered tumor necrosis factor (TNF). He founded Celularity and previously served as its CEO, developing placenta-derived cell therapies and biomaterials; he also holds faculty positions at Weill Cornell Medical College and has authored numerous scientific publications and patents in stem cell biology.
JD
Joseph DosSantosinSVP, Finance and Interim CFO2017–2026Joseph DosSantos is Chief Financial Officer of Celularity, a regenerative medicine company developing cell therapies and biomaterials from placenta-derived cells. He brings financial leadership experience spanning reporting, accounting operations, capital raising, and deal structuring, with particular expertise in GAAP compliance and pharmaceutical industry accounting.
JR
John R. HainesinAnalyst
SA
Stephen A. BrigidoinPresident- Functional Regeneration2019–2026
BG
Bradley GloverExecutive
AL
Andrew L. PecorainFounding DirectorAndrew Pecora is a hematologist and oncologist with expertise in stem cell transplantation and cellular medicine who previously served as President of Physician Enterprise and Chief Innovation Officer at Hackensack Meridian Health, where he expanded the John Theurer Cancer Center and led research initiatives. He founded Cota, a healthcare analytics company, and led Outcomes Matter Innovations as CEO before joining Celularity as Executive Officer.
MB
Mohit BhatiaExecutive
CQ
Curtis QuigleyinSenior Vice President, Commercial Operations2017–2019Curtis Quigley holds a Bachelor of Science in Agricultural Economics from the University of Illinois at Urbana-Champaign and brings senior commercial leadership experience in biotechnology, with background in oncology and managed care. He serves as an Executive Officer at Celularity, a regenerative medicine company developing cell therapies and biomaterials derived from placental tissue.
TS
Timothy SmithinExecutive Vice President and General Counsel2017–2019He brings expertise in corporate law, intellectual property strategy, and regulatory compliance for clinical research, with experience building in-house legal and IP functions at life sciences companies.
BS
Beth SteinbrennerinExecutive Vice President Human Resources2018–2023Beth Steinbrenner is an executive with extensive HR leadership experience across multiple industries, including expertise in talent acquisition, employee relations, and HR strategy alignment with business objectives.
LK
Lim Kok ThayNamed on SEC filing
JS
John SculleyNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$159.5M disclosed across 7 rounds · 2017–2025
▶$2MraisedNov 2025 · 1 investors · BiotechnologyRule 506(c)
▶$2MraisedNov 2025 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Diane ParksDirector
- Peter DiamandisDirector
- John R. HainesExecutive Officer
- Vincent LeVienDirector
- Joseph DosSantosExecutive Officer
- Robert J. HaririExecutive Officer, Director
- Geoffrey LingDirector
- Stephen A. BrigidoExecutive Officer
- Offering amount
- $6.7M
- Amount sold
- $2M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2MraisedAug 2025 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedAug 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert J. HaririExecutive Officer, Director
- Stephen A. BrigidoExecutive Officer
- John R. HainesExecutive Officer
- Diane ParksDirector
- Vincent LeVienDirector
- Peter DiamandisDirector
- Joseph DosSantosExecutive Officer
- Geoffrey LingDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.8MraisedAug 2025 · 1 investors · BiotechnologyRule 506(b)
▶$6.8MraisedAug 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vincent LeVienDirector
- Robert J. HaririExecutive Officer, Director
- Joseph DosSantosExecutive Officer
- Peter DiamandisDirector
- John R. HainesExecutive Officer
- Geoffrey LingDirector
- Stephen A. BrigidoExecutive Officer
- Diane ParksDirector
- Offering amount
- $6.8M
- Amount sold
- $6.8M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedAug 2025 · 14 investors · BiotechnologyRule 506(b)
▶$1MraisedAug 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter DiamandisDirector
- Diane ParksDirector
- Geoffrey LingDirector
- Robert J. HaririExecutive Officer, Director
- Stephen A. BrigidoExecutive Officer
- John R. HainesExecutive Officer
- Joseph DosSantosExecutive Officer
- Vincent LeVienDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedMay 2022 · 1 investors · BiotechnologyRule 506(c)
▶$30MraisedMay 2022 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Bradley GloverExecutive Officer
- Andrew L. PecoraExecutive Officer
- Lim Kok ThayDirector
- John SculleyDirector
- Dean C. KehlerDirector
- Robin L. SmithDirector
- Peter DiamandisDirector
- John R. HainesExecutive Officer
- Andrew C. von EschenbachDirector
- David C. BeersExecutive Officer
- Marc MazurDirector
- Jay BloomDirector
- Robert J. HaririExecutive Officer, Director
- Keary DunnExecutive Officer
- Stephen A. BrigidoExecutive Officer
- Anne JonesExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $2.1M
- Placement agents
- A.G.P/ Alliance Global Partners
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06c
▶$77.7MraisedNov 2018 · 5 investors · BiotechnologyRule 506(b)
▶$77.7MraisedNov 2018 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph KaminskiExecutive Officer
- Carlos RamirezExecutive Officer
- Gertjan BartlemaExecutive Officer
- John SculleyDirector
- Beth SteinbrennerExecutive Officer
- David LemusDirector
- Henry JiDirector
- Tim SmithExecutive Officer
- Andrew PecoraDirector
- Jaisim ShahDirector
- Xiaokui ZhangExecutive Officer
- Nassir HabboubiExecutive Officer
- Andrew von EschenbachDirector
- Jodi GurneyExecutive Officer
- Curtis QuigleyExecutive Officer
- Bill WallerExecutive Officer
- Peter DiamandisDirector
- Kok Thay LimDirector
- John HainesExecutive Officer
- Robert HaririExecutive Officer, Director
- Bill MarisDirector
- Offering amount
- $202.7M
- Amount sold
- $77.7M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$40MraisedSep 2017 · 16 investors · BiotechnologyRule 506(b)
▶$40MraisedSep 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bill MarisDirector
- Mohit BhatiaExecutive Officer
- Jaisim ShahDirector
- John R. HainesExecutive Officer
- Robert HaririExecutive Officer, Director
- Curtis QuigleyExecutive Officer
- Timothy SmithExecutive Officer
- David DemingDirector
- Henry JiDirector
- Andrew von EschenbachDirector
- Peter DiamandisDirector
- Beth SteinbrennerExecutive Officer
- Andrew PecoraDirector
- Henry BrockExecutive Officer
- John ScullyDirector
- William WallerExecutive Officer
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Cellarity30 shared keywordsCellarity develops medicines using artificial intelligence and single-cell biology to address disease at the cellular level rather than targeting individual disease markers. The company serves patients with challenging diseases through AI-driven drug discovery.
Kite Pharma28 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Cellares26 shared keywordsCellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies. The company serves biopharmaceutical manufacturers and cell therapy developers worldwide.
Companies competing with Celularity for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Celularity do?
- Celularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.
- Who founded Celularity?
- Celularity was founded by Robert J. Hariri in 2018.
- Who are Celularity's investors?
- Celularity's investors include Blue Ivy Ventures, Castor Ventures (an Alumni Ventures Fund), Bold Capital Partners.
- How much funding has Celularity raised?
- Celularity has disclosed $159.5M raised across 7 rounds.
- Where is Celularity headquartered?
- Celularity is headquartered in Florham Park, US.